By a News Reporter-Staff News Editor at Women's Health Weekly -- New research on Biotechnology is the subject of a report. According to news reporting out of Notre Dame, Indiana, by NewsRx editors, research stated, "Ligand-targeted nanoparticles are emerging drug delivery vehicles for cancer therapy. Here, we demonstrate that the cellular uptake of peptide-targeted liposomes and micelles can be significantly enhanced by increasing the hydrophilicity of the targeting peptide sequence while simultaneously optimizing the EG peptide-linker length."
Our news journalists obtained a quote from the research from the University of Notre Dame, "Two distinct disease models were analyzed, as the nanoparticles were functionalized with either VLA-4 or HER2 antagonistic peptides to target multiple myeloma or breast cancer cells, respectively. Our results demonstrated that including a short oligolysine chain adjacent to the targeting peptide sequence effectively increased cellular uptake of targeted nanoparticles up to similar to 80-fold using an EG6 peptide-linker in liposomes and similar to 27-fold using an EG18 peptide-linker in micelles for the VLA-4/multiple myeloma system. Similar trends were also observed in the HER2/breast cancer system with the EG18 peptide-linker resulting in optimal uptake for both types of nanoparticles. Cellular uptake efficiency of these formulations was also confirmed under fluidic conditions mimicking physiological systems."
According to the news editors, the research concluded: "Taken together, these results demonstrated the significance of using the right design elements to improve the cellular uptake of nanoparticles."
For more information on this research see: Enhanced Cellular Uptake of Peptide-Targeted Nanoparticles through Increased Peptide Hydrophilicity and Optimized Ethylene Glycol Peptide-Linker Length. ACS Nano, 2013;7(9):8115-8127. ACS Nano can be contacted at: Amer Chemical Soc, 1155 16TH St, NW, Washington, DC 20036, USA. (American Chemical Society - www.acs.org; ACS Nano - www.pubs.acs.org/journal/ancac3)
Our news journalists report that additional information may be obtained by contacting J.F. Stefanick, University of Notre Dame, Notre Dame, IN 46556, United States. Additional authors for this research include J.D. Ashley and B. Bilgicer (see also technology.html">Biotechnology).
Keywords for this news article include: Biotechnology, Cancer, Indiana, Alkenes, Therapy, Oncology, Liposomes, Notre Dame, Nanoparticle, United States, Nanotechnology, Ethylene Glycols, Drug Delivery Systems, Emerging Technologies, North and Central America
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC